INTRODUCTION
Skeletal muscle development is known to be dependent on a family of basic helix-loop-helix (bHLH) transcription factors, termed the myogenic regulatory factors (MRFs). The family includes MyoD, myf5, myogenin and myf6/MRF4/herculin (1-7).
Ectopic expression of any family member in a wide range of non-muscle cells results in the conversion of these cells to the skeletal muscle lineage (8, 9) . The myogenic regulatory factors regulate muscle-specific gene expression by heterodimerizing with the E type family of ubiquitous bHLH transcription factors via the HLH domains and binding the E box consensus sequence (CANNTG) within muscle-specific promoters via the basic domains (10, 11) . Homodimers of MyoD are inactive while heterodimers between MyoD and E type proteins can activate E box-containing promoters.
Therefore, heterodimerization with the E type transcription factors is necessary for activity of the myogenic regulatory factors.
The E type family of bHLH transcription factors includes E12/E47 (12-14), ITF-2 (15) (16) (17) , and HEB (18). The E type proteins contain two activation domains, the AD1 domain and the AD2 or LH domain (19, 20) . Two alternatively spliced forms of mouse ITF-2, termed ITF-2A and ITF-2B, were shown to differentially regulate MyoD activation. In transient transfection assays, ITF-2B was found to inhibit MyoD activation of the cardiac -actin muscle-specific promoter (21) and the muscle-specific creatine 4
The activity of the myogenic regulatory factors is also inhibited by the Id gene family (23) . These factors contain a HLH domain but lack a basic domain. They are thought to inhibit the activity of the myogenic factors by forming inactive heterodimers with the E type proteins, thus sequestering them from myogenic factor binding (23, 24) .
Several studies suggest this is not the primary mechanism by which inhibition by ITF-2B occurs. Inhibition by Id can be reversed by the addition of excess E type activator, while inhibition by ITF-2B cannot (21). Further, MyoD/ITF-2B heterodimers bind DNA (22). Together, these results suggest that ITF-2B can form a stable heterodimer with MyoD, which can then bind the E box consensus, but this complex is unable to activate transcription.
Basic helix-loop-helix transcription factors have also been shown to inhibit MyoD activity. Twist inhibits MyoD activity by mechanisms involving the titration and sequestration of the E types, by inhibition of the MyoD co-factor MEF2 and direct inhibition via interaction with the basic domain of MyoD (25) (26) (27) . MyoR has also been shown to inhibit MyoD activity by mechanisms including competition for DNA binding sites, active repression through a repressor domain and titration of the E type proteins (28). More recently, the bHLH protein OUT, has been shown to inhibit MyoD activity by E type titration and by preventing E12-MyoD heterodimers from binding DNA (29).
Here we set out to examine the role of the N-terminal domain of ITF-2B in the inhibition of MyoD activity. We found that the full length E12/E47 proteins contain a domain that is highly similar to the N-terminal inhibitory region of ITF-2B. Like ITF-2B, both full length E12 and E47 proteins were shown to inhibit transactivation of the exogenous cardiac -actin promoter by MyoD. The fragment from aa 11-28 was amplified using the following oligonucleotides:
AAAGGTACC ATG GGGACGGACAAAGAGCTG and AAAGGTACCGGAGGCGAA β-galactosidase and chloramphenicol acetyltransferase (CAT) assays were performed as previously described (37, 38) . β-galactosidase activities for each culture were normalized for transfection efficiency against CAT activity as well as to the activity Anti-mouse Ig, horseradish peroxidase linked whole antibody (Amersham Life Sciences, Oakville, ON, Canada) secondary antibody was used at a 1:5000 dilution.
The reaction was visualized using the ECL SuperSignal Substrate (Pierce, Rockford, 9 IL) for western blotting and autoradiography. Quantitation was carried out utilizing NIH Image 1.58.
Northern Blot Analysis -The lithium chloride/urea extraction method was used to isolate total RNA, and 6 g were examined by Northern blot analysis as previously 
RESULTS

Full length E12 and E47 inhibit MyoD activity -Previous results have shown that
the amino-terminal 83 amino acids of ITF-2B were required for ITF-2B to inhibit MyoD activity (21). Consequently, we set out to determine if other E type proteins contained similar N-terminal sequences and possibly, similar inhibitory activity. An alignment of the N-terminal 83 amino acids with the N-termini of full length E12 and full length E47 (33) revealed that this domain is 51% identical among the three E type proteins (Fig 1) .
This region has been shown to contain a conserved α-helix that functions as a transactivation domain when fused to the Gal4 DNA binding domain (34) . The E12
and E47 proteins, termed ∆E12 and ∆E47, utilized in activation studies with MyoD, are fragments of the full length proteins and contain a synthetic initiator methionine (12).
These fragments are missing the first 216 aa compared to full length E12 and E47 (33).
Subsequently, the partial proteins are missing the region that is similar to the Nterminal region of the inhibitor ITF-2B (summarized in Fig. 2A ). To our knowledge, the full length E12 and E47 proteins have not been tested with respect to their effect on MyoD activity.
In order to determine if the presence of the conserved N-terminal region (represented in Fig. 1 ) modified the activity of E12 and E47, we examined the effect of full length E12 and E47 proteins on MyoD. This involved determining the ability of (Fig. 2B) .
Furthermore, MyoD was active in the presence of ∆E12 and ITF-2A but not in the presence of ITF-2B. In the presence of full length E12 and full length E47, MyoD activity was decreased 3 and 5-fold, respectively, in multiple repetitive assays.
Therefore, full length E12 and E47 proteins inhibited MyoD activity as effectively as ITF-2B.
Mutation of the conserved -helix does not affect inhibition -A conserved α-
helix has been identified from aa 11-28 of E12, E47, and ITF-2B that functions as a transcriptional activator when fused to the Gal4 DNA binding domain (34) . Since this region lies within the inhibitory domain of ITF-2B and can interact with components of the transcriptional machinery, we set out to determine if these sequences were required for inhibition. A mutant was generated in which 2 conserved, non-polar residues were replaced with arginine (Fig. 3A) . These changes were shown previously to disrupt the transactivation domain (34). Here we show that this mutant still functions as an inhibitor, decreasing MyoD activity 4-fold compared to MyoD alone (Fig. 3B) . fold. This range of inhibition may be due to small variations in conformation or expression levels between the different fusion proteins. This conversion did not appear to be sequence dependent since both non-inhibitory sequences from ITF-2A
Lengthening the N-terminus of E12 converts the activator into an inhibitor -
and inhibitory sequences from ITF-2B were capable of converting ∆E12 into an inhibitor. Consequently, as few as 18 amino acids are sufficient to convert ∆E12 from an activator into an inhibitor, in a sequence independent manner.
Overexpression of ITF-2B has no effect on myogenesis or fibre type generation -
To study the physiological relevance of ITF-2B inhibition of MyoD activity, ITF-2B was stably and transiently overexpressed in C2C12 myoblasts. Cells stably expressing ITF-2B, ITF-2A or ∆E12 were differentiated to determine if overexpression of ITF-2B was sufficient to inhibit the process of myogenesis (Fig. 5) . The differentiation of C2C12 myoblasts was monitored by counting colonies that contained multinucleated myotubes and overexpression of the E type proteins was determined by in situ hybridization. Myotubes were found to express high levels of ITF-2B (Fig. 5A ), compared to endogenous staining ( The fusion of activating sequences from ITF-2A or inhibitory sequences from ITF-2B onto the N-terminus of ∆E12 converted ∆E12 from an activator into an inhibitor.
Since the inhibition was sequence-independent, it is possible that the fusion of ectopic sequences may change the conformation of the amino terminus of E12, transforming it from an activator into an inhibitor. This conformational change may simulate the mechanism by which ITF-2B inhibits MyoD activity via its N-terminal domain. by guest on January 8, 2018
